Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes?

Publication date: 5 July 2017
Source:Cell Metabolism, Volume 26, Issue 1
Author(s): Sandrine Paule Claus
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.

Teaser

Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.


http://ift.tt/2tlN6m0